Privia Health Group (PRVA) Set to Announce Earnings on Thursday

Privia Health Group (NASDAQ:PRVA) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Privia Health Group to post earnings of $0.05 per share for the quarter. Privia Health Group has set its FY 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.

Privia Health Group (NASDAQ:PRVA) last released its earnings results on Tuesday, February 27th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The business had revenue of $440.80 million for the quarter, compared to the consensus estimate of $425.81 million. During the same quarter in the previous year, the company earned $0.14 earnings per share. The firm’s revenue for the quarter was up 21.0% on a year-over-year basis. On average, analysts expect Privia Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Privia Health Group Price Performance

NASDAQ PRVA opened at $18.03 on Thursday. Privia Health Group has a fifty-two week low of $17.54 and a fifty-two week high of $30.15. The stock has a market capitalization of $2.14 billion, a PE ratio of 94.89, a PEG ratio of 2.55 and a beta of 0.81. The business has a fifty day moving average price of $19.71 and a two-hundred day moving average price of $21.18.

Insider Activity at Privia Health Group

In related news, CFO David Mountcastle sold 3,933 shares of the firm’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total value of $69,889.41. Following the transaction, the chief financial officer now owns 262,279 shares of the company’s stock, valued at approximately $4,660,697.83. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 14.20% of the stock is owned by insiders.

Analyst Ratings Changes

PRVA has been the subject of a number of recent research reports. Evercore ISI decreased their price objective on Privia Health Group from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th. JPMorgan Chase & Co. decreased their price objective on Privia Health Group from $38.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 6th. Stifel Nicolaus decreased their price objective on Privia Health Group from $28.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday. Bank of America downgraded Privia Health Group from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $27.00 to $21.00 in a report on Thursday, February 22nd. Finally, Canaccord Genuity Group decreased their price objective on Privia Health Group from $41.00 to $37.00 and set a “buy” rating for the company in a report on Tuesday, March 19th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.62.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.